Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lymphoma Clinical Trials in Dallas | 304 Studies

Clinical Trials LymphomaDallas

Lymphoma Clinical Trials in Dallas

Find 304 clinical trials for lymphoma near Dallas, Texas. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 181-200 of 304 trials

TerminatedA Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsThis study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than…NCT04644315·Culver City, California and 28 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

AvailableExpanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelThe goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is…NCT05776134·Birmingham, Alabama and 43 others

CompletedA Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).NCT03292406·Orange, California and 20 others

CompletedA Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin LymphomaThis study is a Phase 1/2 open-label three part study in patients with relapsed indolent Non-Hodgkin's lymohoma (NHL) (Parts A and C) or relapsed/refractory follicular lymphoma…NCT01796171·Little Rock, Arkansas and 95 others

TerminatedA Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe…NCT03138499·Duarte, California and 21 others

Active not recruitingA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05451810·Mobile, Alabama and 71 others

TerminatedS0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00006708·Mobile, Alabama and 84 others

TerminatedFT516 in Subjects With Advanced Hematologic MalignanciesThis is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma.NCT04023071·Phoenix, Arizona and 6 others

CompletedDiagnostic Study of Patients With Aggressive Non-Hodgkin's LymphomaRATIONALE: Determination of genetic markers for aggressive non-Hodgkin's lymphoma may help identify patients with this disease and help predict the outcome of treatment.NCT00003863·Anniston, Alabama and 68 others

RecruitingA Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesThis is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell…NCT04830137·Duarte, California and 15 others

CompletedA Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are…NCT03744676·Los Angeles, California and 22 others

RecruitingA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPhase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies…NCT04094610·Los Angeles, California and 67 others

Active not recruitingUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin…NCT03698994·Birmingham, Alabama and 106 others

RecruitingA Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesThis Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax…NCT06708897·Louisville, Kentucky and 4 others

CompletedTrial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell LymphomaThis study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in…NCT03677154·Birmingham, Alabama and 31 others

RecruitingA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or…NCT06022029·Los Angeles, California and 15 others

TerminatedA Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisThe main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.NCT01163253·Birmingham, Alabama and 322 others

CompletedDose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesA two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination…NCT03397706·Los Angeles, California and 27 others

Active not recruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations…NCT03210714·Birmingham, Alabama and 115 others

Active not recruitingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK…NCT02568267·Phoenix, Arizona and 119 others

PreviousPage 10 of 16Next

Other Conditions in Dallas

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia